克唑替尼一線治療外周血下一代測序技術檢測 <i>ROS1</i> 陽性晚期多合并癥肺腺癌一例 _West China Medical Journal

Authors：

張瑜 ,  彭楓

四川大學華西醫院胸部腫瘤科（成都 610041）;

Corresponding?author：

彭楓, Email: pfwork@126.com

Keywords：

肺腺癌; 外周血下一代測序技術; ROS1 基因; 靶向治療; 克唑替尼

DOI：

10.7507/1002-0179.201611164

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 張瑜, 彭楓. 克唑替尼一線治療外周血下一代測序技術檢測 ROS1 陽性晚期多合并癥肺腺癌一例 . West China Medical Journal, 2017, 32(12): 2024-2026. doi: 10.7507/1002-0179.201611164 Copy

1.	Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153): 561-566.
2.	Rikova K, Guo AL, Zeng QF, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131(6): 1190-1203.
3.	Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol, 2012, 13(10): 1011-1019.
4.	Crinò L, Kim D, Riely GJ, et al. Initial phaseⅡ results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol, 2011, 29(S 15): 7514.
5.	董江萍. FDA 批準克里唑替尼及其基因測試法治療晚期非小細胞肺癌. 藥物評價研究, 2011, 34(5): 402.
6.	Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res, 2012, 22(11): 2109-2119.
7.	Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 2012, 30(8): 863-870.
8.	Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014, 371(21): 1963-1971.

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153): 561-566.
2. Rikova K, Guo AL, Zeng QF, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131(6): 1190-1203.
3. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol, 2012, 13(10): 1011-1019.
4. Crinò L, Kim D, Riely GJ, et al. Initial phaseⅡ results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol, 2011, 29(S 15): 7514.
5. 董江萍. FDA 批準克里唑替尼及其基因測試法治療晚期非小細胞肺癌. 藥物評價研究, 2011, 34(5): 402.
6. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res, 2012, 22(11): 2109-2119.
7. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 2012, 30(8): 863-870.
8. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014, 371(21): 1963-1971.

Previous Article
抗結核藥致剝脫性皮炎一例
Next Article
慢性胰腺炎患者術后并發盆腔腹膜后膿腫護理一例

West China Medical Journal

克唑替尼一線治療外周血下一代測序技術檢測 ROS1 陽性晚期多合并癥肺腺癌一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content